Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

117.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott Laboratories reported third-quarter 2024 sales of $10.64B, with Medical Devices leading 11.7% sales growth. Adjusted EPS of $1.21 beat analyst expectations. Full-year guidance was updated. 
Via Benzinga
Abbott Labs Earnings Edge Past Q3 Views, Led By Medical Devices
Medical devices led organic sales growth. 
Via Investor's Business Daily
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
A Glimpse of Abbott Laboratories's Earnings Potential
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock
Via Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
How Is The Market Feeling About Abbott Laboratories?
Via Benzinga
Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone
Via Benzinga
Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Columbus Day: Is Stock Market Open Today?
Investors should brace for a busy week with earnings reports from major companies. 
Via Benzinga
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion. 
Via Benzinga
Navigating 6 Analyst Ratings For Abbott Laboratories
Via Benzinga
Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors.
Is ABBOTT LABORATORIES (NYSE:ABT) a Strong Candidate for Quality Investing? 
Via Chartmill
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Investors can find market-trouncing blue chip stocks in the healthcare industry. 
Via The Motley Fool
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Down More Than 50%, Is DexCom Stock a Bargain Now?
Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market. 
Via The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation. 
Via Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market is divided on the magnitude of the cut, which could trigger significant... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
The dividend growth powerhouse is turning the corner. 
Via The Motley Fool
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
The company continues to flex its innovative muscles. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
These stocks have increased their payouts for decades. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.